Citations (183)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (33)
Xinmei Liao, Hui Liang, Jian Pan, Qian Zhang, Jiaqi Niu, Cuili Xue, Jian Ni & Daxiang Cui. (2021) Preparation and characterization of a fully human monoclonal antibody specific for human tumor necrosis factor alpha. Bioengineered 12:2, pages 10821-10834.
Read now
Read now
Leticia Garcia-Montoya & Paul Emery. (2021) Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs 30:11, pages 1109-1124.
Read now
Read now
Ana Teresa Melo, Raquel Campanilho-Marques & João Eurico Fonseca. (2021) Golimumab (anti-TNF monoclonal antibody): where we stand today. Human Vaccines & Immunotherapeutics 17:6, pages 1586-1598.
Read now
Read now
Min Wu, Jixuan Sun, Dandan Wu, Jia Xu, Jin Wei, Zhaohe Wang, Jinchen Yu, Shengfeng Li, Hong Zhang & Yanhua Ding. (2021) A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects. Expert Opinion on Investigational Drugs 30:1, pages 77-83.
Read now
Read now
Tomohito Wakabayashi, Keiko Hosohata, Saki Oyama, Ayaka Inada, Sayaka Ueno, Hiroko Kambara, Tatsuya Iida, Takahiro Nakatsuji, Mayako Uchida & Kazunori Iwanaga. (2020) Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database. Therapeutics and Clinical Risk Management 16, pages 741-747.
Read now
Read now
Songmao Zheng, Fang Shen, Brian Jones, Damien Fink, Brian Geist, Ivo Nnane, Zhao Zhou, Jeff Hall, Ravi Malaviya, Tatiana Ort & Weirong Wang. (2020) Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. mAbs 12:1.
Read now
Read now
Maria Soledad Ormaechea, Muhammad Hassan, Neil Onghanseng, Jung Hyun Park, Sarakshi Mahajan, Khalid Yusuf Al-Kirwi, Gunay Uludag, Muhammad Sohail Halim, Ariel Schlaen, Yasir J Sepah, Diana V Do & Quan Dong Nguyen. (2019) Safety of systemic therapy for noninfectious uveitis. Expert Opinion on Drug Safety 18:12, pages 1219-1235.
Read now
Read now
Thorvardur Jon Love & Arthur Kavanaugh. (2018) Golimumab in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 14:11, pages 893-898.
Read now
Read now
Mathurin Flamant, Stephane Paul & Xavier Roblin. (2017) Golimumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 17:7, pages 879-886.
Read now
Read now
Anne S. Strik, Sophie E. Berends, Ron A. Mathôt, Geert R. D’Haens & Mark Löwenberg. (2017) Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 11:5, pages 401-406.
Read now
Read now
Carlo Palazzi, Salvatore D’angelo, Michele Gilio, Pietro Leccese, Angela Padula & Ignazio Olivieri. (2017) Golimumab for the treatment of axial spondyloarthritis. Expert Opinion on Biological Therapy 17:1, pages 129-133.
Read now
Read now
Daniela Pugliese, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi & Alessandro Armuzzi. (2016) Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug, Healthcare and Patient Safety 8, pages 1-7.
Read now
Read now
Andrea Matucci, Daniele Cammelli, Fabrizio Cantini, Delia Goletti, Valentina Marino, Giuseppe Maria Milano, Raffaele Scarpa, Giuliano Tocci, Enrico Maggi & Alessandra Vultaggio. (2016) Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. Expert Opinion on Drug Safety 15:sup1, pages 3-10.
Read now
Read now
Saurabh Kedia, Vineet Ahuja & Govind K. Makharia. (2016) Golimumab for moderately to severely active ulcerative colitis. Expert Review of Clinical Pharmacology 9:10, pages 1273-1282.
Read now
Read now
Richard K. Russell, Richard Hansen & Dan Turner. (2016) New treatments for ulcerative colitis: do we have pediatric data?. Expert Review of Clinical Immunology 12:7, pages 701-704.
Read now
Read now
María Chaparro & Javier P. Gisbert. (2016) Maintenance therapy options for ulcerative colitis. Expert Opinion on Pharmacotherapy 17:10, pages 1339-1349.
Read now
Read now
Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Yutaka Ishii, Hiroshi Nakajima, Daniel Baker, Nobuyuki Miyasaka & Takao Koike. (2016) Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. Modern Rheumatology 26:3, pages 323-330.
Read now
Read now
Yoshiya Tanaka, Asako Senoo, Hideji Fujii & Daniel Baker. (2016) Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opinion on Drug Metabolism & Toxicology 12:3, pages 319-326.
Read now
Read now
Marc Berns & Daniel W. Hommes. (2016) Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 25:2, pages 129-143.
Read now
Read now
Rebecca Fausel & Anita Afzali. (2015) Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists. Therapeutics and Clinical Risk Management 11, pages 63-73.
Read now
Read now
Walter Reinisch, Edouard Louis & Silvio Danese. (2015) The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Expert Review of Gastroenterology & Hepatology 9:sup1, pages 17-26.
Read now
Read now
Ulf Müller-Ladner, SeungSuh Hong, Choongseob Oh & Peter Taylor. (2015) Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. Expert Review of Clinical Immunology 11:sup1, pages 5-14.
Read now
Read now
Ian C Lawrance. (2015) Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opinion on Investigational Drugs 24:6, pages 761-768.
Read now
Read now
Francesco Semeraro, Barbara Arcidiacono, Giuseppe Nascimbeni, Martina Angi, Barbara Parolini & Ciro Costagliola. (2014) Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Design, Development and Therapy 8, pages 341-348.
Read now
Read now
Mark Löwenberg, Nanne KH de Boer & Frank Hoentjen. (2014) Golimumab for the treatment of ulcerative colitis. Clinical and Experimental Gastroenterology 7, pages 53-59.
Read now
Read now
Paulo César Martins Urbano, Vanete Thomaz Soccol & Valderilio Feijó Azevedo. (2014) Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics: Targets and Therapy 8, pages 211-220.
Read now
Read now
Silvano Sozzani, Maria P. Abbracchio, Vito Annese, Silvio Danese, Ornella De Pità, Giovambattista De Sarro, Sabatino Maione, Ignazio Olivieri, Aurora Parodi & Piercarlo Sarzi-Puttini. (2014) Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity 47:5, pages 287-306.
Read now
Read now
Svend T Rietdijk & Geert R D’Haens. (2014) Vedolizumab for the treatment of ulcerative colitis. Expert Review of Clinical Pharmacology 7:4, pages 423-430.
Read now
Read now
Thomas Billiet, Paul Rutgeerts, Marc Ferrante, Gert Van Assche & Séverine Vermeire. (2014) Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 14:1, pages 75-101.
Read now
Read now
Seiji Minota. (2013) Physico-chemical characteristics of TNFα blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds. Modern Rheumatology 23:5, pages 1034-1036.
Read now
Read now
Giovanni Monteleone, Francesco Pallone & Flavio Caprioli. (2013) Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opinion on Investigational Drugs 22:9, pages 1123-1132.
Read now
Read now
Vera Kandror Denmark & Lloyd Mayer. (2013) Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 9:1, pages 77-92.
Read now
Read now
Daniel R. Getts, Meghann T. Getts, Derrick P. McCarthy, Emily ML Chastain & Stephen D. Miller. (2010) Have we overestimated the benefit of human(ized) antibodies?. mAbs 2:6, pages 682-694.
Read now
Read now
Articles from other publishers (150)
Paulo Lizano, Sovannarath Pong, Stephanie Santarriaga, Deepthi Bannai & Rakesh Karmacharya. (2023) Brain microvascular endothelial cells and blood-brain barrier dysfunction in psychotic disorders. Molecular Psychiatry.
Crossref
Crossref
Matteo Sensi, Rafael Furlan de Oliveira, Marcello Berto, Marina Palmieri, Emilio Ruini, Pietro Antonio Livio, Andrea Conti, Marcello Pinti, Carlo Salvarani, Andrea Cossarizza, Joan M. Cabot, Jordi Ricart, Stefano Casalini, María Begoña González‐García, Pablo Fanjul‐Bolado, Carlo Augusto Bortolotti, Paolo Samorì & Fabio Biscarini. (2023) Reduced Graphene Oxide Electrolyte‐Gated Transistor Immunosensor with Highly Selective Multiparametric Detection of Anti‐Drug Antibodies. Advanced Materials.
Crossref
Crossref
Bimlesh Dhar Pandey, Venkataraman Krishnamurthy, Uma Kumar, Sundeep Kumar Upadhyaya, Neeraj Jain, Manish Dugar, Sagar Panchal, Nishita Shah, Tanuja Korde & Jitendra Dixit. (2023) Safety and Efficacy of Golimumab in Rheumatoid Arthritis: A Prospective, Multicenter, Real-World Study from India. Indian Journal of Rheumatology.
Crossref
Crossref
Shandor Erdes, Ekaterina M. Agafonova, Daria G. Timokhina, Satenik Y. Davidian, Elena V. Zemerova, Aleksey I. Kulikov, Olga G. Markova & Vladimir F. Achikyan. (2023)
Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor‐α inhibitor golimumab: Results of a
24‐Month
prospective observation study (
GO‐COX
Study)
. International Journal of Rheumatic Diseases 26:7, pages 1321-1329.
Crossref
Crossref
Xiaoli Pan, Sheila N. López Acevedo, Camille Cuziol, Evelyn De Tavernier, Ahmed S. Fahad, Priyobarta S. Longjam, Sambasiva P. Rao, David Aguilera-Rodríguez, Mathilde Rezé, Christine A. Bricault, Matías F. Gutiérrez-González, Matheus Oliveira de Souza, Joshua M. DiNapoli, Emmanuelle Vigne, Melody A. Shahsavarian & Brandon J. DeKosky. (2023) Large-scale antibody immune response mapping of splenic B cells and bone marrow plasma cells in a transgenic mouse model. Frontiers in Immunology 14.
Crossref
Crossref
Jill L. Kinzer, Troy A. Halseth, Jukyung Kang, Sang Yeop Kim, Preethi Kumaran, Michael Ford, Sergei Saveliev, St John Skilton & Anna Schwendeman. (2023) Physicochemical characterization and functionality comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria® (golimumab). International Journal of Pharmaceutics 635, pages 122646.
Crossref
Crossref
Gian Marco Leone, Katia Mangano, Maria Cristina Petralia, Ferdinando Nicoletti & Paolo Fagone. (2023) Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. Journal of Clinical Medicine 12:4, pages 1630.
Crossref
Crossref
Albert J. Czaja. (2022) Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Digestive Diseases and Sciences 67:11, pages 4979-5005.
Crossref
Crossref
Flávia Oliveira de Lima, Pedro Santana Sales Lauria, Renan Fernandes do Espírito-Santo, Afrânio Ferreira Evangelista, Tâmara Magalhães Oliveira Nogueira, Dionéia Araldi, Milena Botelho Pereira Soares & Cristiane Flora Villarreal. (2022) Unveiling Targets for Treating Postoperative Pain: The Role of the TNF-α/p38 MAPK/NF-κB/Nav1.8 and Nav1.9 Pathways in the Mouse Model of Incisional Pain. International Journal of Molecular Sciences 23:19, pages 11630.
Crossref
Crossref
Ryan Ha, Yoav Keynan & Zulma Vanessa Rueda. (2022) Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim, Seung-Geun Lee, Choong Ki Lee, Sang-Cheol Bae, Yong-Beom Park & Yeong Wook Song. (2022) Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. The Korean Journal of Internal Medicine 37:5, pages 1061-1069.
Crossref
Crossref
Bowen Li, Li Yang, Feng Bai, Bainan Tong & Xiaoli Liu. (2022) Indications and effects of biological agents in the treatment of noninfectious uveitis. Immunotherapy 14:12, pages 985-994.
Crossref
Crossref
Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama & Yasuo Suzuki. (2022) Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance. Intestinal Research 20:3, pages 329-341.
Crossref
Crossref
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee & Eric Bartee. (2022) TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. Journal for ImmunoTherapy of Cancer 10:5, pages e004770.
Crossref
Crossref
Tao Liu, Jin Xu, Qingcheng Guo, Dapeng Zhang, Jun Li, Weizhu Qian, Huaizu Guo, Xinli Zhou & Sheng Hou. (2022) Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab. Frontiers in Chemistry 10.
Crossref
Crossref
Hassan Dariushnejad, Leila Chodari, Mehrnoosh Sedighi, Soheila Akbari & Vajihe Ghorbanzadeh. (2022) Rheumatoid arthritis: current therapeutics compendium. Endocrine Regulations 56:2, pages 148-162.
Crossref
Crossref
Marouf M. Alhalabi & Ahmad J. Abbas. (2022) Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. Annals of Medicine and Surgery 75, pages 103456.
Crossref
Crossref
Aina Akmal Mohd Noor, Maryam Azlan & Norhanani Mohd Redzwan. (2022) Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. Biomedicines 10:2, pages 498.
Crossref
Crossref
Kazuhide Tokita, Hirotaka Shimizu, Ichiro Takeuchi, Toshiaki Shimizu & Katsuhiro Arai. (2022) Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan. Pediatric Gastroenterology, Hepatology & Nutrition 25:6, pages 461.
Crossref
Crossref
Rozaleen Dash, Sumit Kumar Singh, Narendra Chirmule & Anurag S. Rathore. (2021) Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review. The AAPS Journal 24:1.
Crossref
Crossref
Nasar Aslam, Sheng Wei Lo, Rafid Sikafi, Tom Barnes, Jonathan Segal, Philip J Smith & Jimmy K Limdi. (2022) A review of the therapeutic management of ulcerative colitis. Therapeutic Advances in Gastroenterology 15, pages 175628482211381.
Crossref
Crossref
Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe & Yasuo Suzuki. (2022) Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan. Inflammatory Intestinal Diseases 7:3-4, pages 128-138.
Crossref
Crossref
Zlatko Dembic. 2022. Encyclopedia of Infection and Immunity. Encyclopedia of Infection and Immunity
170
192
.
Nohemí Salinas-Jazmín, Emilio Medina-Rivero & Marco Antonio Velasco-Velázquez. 2022. Therapeutic Antibodies. Therapeutic Antibodies
281
294
.
Antonio Tursi. (2022) Performances of anti-TNFα antibodies as long-term maintenance therapy for ulcerative colitis. European Journal of Gastroenterology & Hepatology 33:1S, pages e1107-e1108.
Crossref
Crossref
Maria del Mar Melendez-Gonzalez, Judy Hamad & Christopher Sayed. (2021) Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure. Journal of Investigative Dermatology 141:12, pages 2975-2979.
Crossref
Crossref
Viana Manrique‐Suárez, Luis Macaya, Maria Angélica Contreras, Natalie Parra, Rafael Maura, Alaín González, Jorge R. Toledo & Oliberto Sánchez. (2021)
Design and characterization of a novel dimeric blood–brain barrier penetrating
TNFα
inhibitor
. Proteins: Structure, Function, and Bioinformatics 89:11, pages 1508-1521.
Crossref
Crossref
Melih PAMUKCU & Rabia AYDOGAN BAYKARA. (2021) Which anti-TNF is most effective for my patient? Which one should I choose?. Journal of Surgery and Medicine 5:9, pages 941-945.
Crossref
Crossref
Hiroki Wakabayashi, Nobuto Nagao, Hitoshi Inada, Yosuke Nishioka, Masahiro Hasegawa, Kusuki Nishioka & Akihiro Sudo. (2021) Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study. Drugs in R&D 21:3, pages 351-357.
Crossref
Crossref
S. Arora, P. R. Cooper, L. T. Friedlander, S. Rizwan, B. Seo, A. M. Rich & H. M. Hussaini. (2021) Potential application of immunotherapy for modulation of pulp inflammation: opportunities for vital pulp treatment. International Endodontic Journal.
Crossref
Crossref
Dan-in Jang, A-Hyeon Lee, Hye-Yoon Shin, Hyo-Ryeong Song, Jong-Hwi Park, Tae-Bong Kang, Sang-Ryong Lee & Seung-Hoon Yang. (2021) The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. International Journal of Molecular Sciences 22:5, pages 2719.
Crossref
Crossref
Ki-Uk Kim, Jisu Kim, Wan-Hoon Kim, Hyeyoung Min & Chang Hwan Choi. (2021) Treatments of inflammatory bowel disease toward personalized medicine. Archives of Pharmacal Research 44:3, pages 293-309.
Crossref
Crossref
Judith Pichler, Nima Memaran, Wolf Dietrich Huber, Christoph Aufricht & Bettina Bidmon‐Fliegenschnee. (2020) Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody. Acta Paediatrica 110:2, pages 661-667.
Crossref
Crossref
Lisia Barros Ferreira, Anthony J. SmithJustine R. Smith. (2021) Biologic Drugs for the Treatment of Noninfectious Uveitis. Asia-Pacific Journal of Ophthalmology 10:1, pages 63-73.
Crossref
Crossref
Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi & Corrado Blandizzi. (2020) Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care 24:1.
Crossref
Crossref
Abhik Bhattacharya & Mark Tomislav Osterman. (2020) Biologic Therapy for Ulcerative Colitis. Gastroenterology Clinics of North America 49:4, pages 717-729.
Crossref
Crossref
Alireza Hejrati, Alireza Rafiei, Mohsen Soltanshahi, Shahnaz Hosseinzadeh, Mina Dabiri, Mahdi Taghadosi, Saeid Taghiloo, Davood Bashash, Fatemeh Khorshidi & Parisa Zafari. (2020) Innate immune response in systemic autoimmune diseases: a potential target of therapy. Inflammopharmacology 28:6, pages 1421-1438.
Crossref
Crossref
Larissa T. Volova, Evgeniy I. Pugachev, Victoria V. Rossinskaya, Violetta V. Boltovskaya, Dmitry A. Dolgushkin & Natalya Ossina. (2020) Rheumatoid Arthritis: Applicability of Ready-to-Use Human Cartilaginous Cells for Screening of Compounds with TNF-Alpha Inhibitory Activity. Biomolecules 10:11, pages 1563.
Crossref
Crossref
Kalliopi Skamaki, Stephane Emond, Matthieu Chodorge, John Andrews, D. Gareth Rees, Daniel Cannon, Bojana Popovic, Andrew Buchanan, Ralph R. Minter & Florian Hollfelder. (2020) In vitro evolution of antibody affinity via insertional scanning mutagenesis of an entire antibody variable region. Proceedings of the National Academy of Sciences 117:44, pages 27307-27318.
Crossref
Crossref
Francesca Penagini, Lucia Cococcioni, Elena Pozzi, Dario Dilillo, Giulia Rendo, Cecilia Mantegazza & Gian Vincenzo Zuccotti. (2020) Biological therapy in pediatric age. Pharmacological Research 161, pages 105120.
Crossref
Crossref
María Angélica Contreras, Luis Macaya, Pedro Neira, Frank Camacho, Alaín González, Jannel Acosta, Raquel Montesino, Jorge Roberto Toledo & Oliberto Sánchez. (2020) New insights on the interaction mechanism of rhTNFα with its antagonists Adalimumab and Etanercept. Biochemical Journal 477:17, pages 3299-3311.
Crossref
Crossref
Sara Žigon-Branc, Ariana Barlič & Matjaž Jeras. 2020. Cytokines. Cytokines.
Keith J. Arlotta, Boi Hoa San, Hong-Hua Mu, S. Michael Yu & Shawn C. Owen. (2020) Localization of Therapeutic Fab-CHP Conjugates to Sites of Denatured Collagen for the Treatment of Rheumatoid Arthritis. Bioconjugate Chemistry 31:8, pages 1960-1970.
Crossref
Crossref
Keigo Koda, Mikio Toyoshima, Tsuyoshi Nozue & Takafumi Suda. (2020) Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature. Internal Medicine 59:16, pages 2015-2021.
Crossref
Crossref
Natalia Kovalova, Jeffrey Boyles, Yi Wen, Derrick R. Witcher, Patricia L. Brown‐Augsburger, Victor J. Wroblewski & Lukasz K. Chlewicki. (2020) Validation of a de‐immunization strategy for monoclonal antibodies using cynomolgus macaque as a surrogate for human. Biopharmaceutics & Drug Disposition 41:3, pages 111-125.
Crossref
Crossref
Biljana Bufan, Ivan Jančić & Zorica Stojić-Vukanić. (2020) Inhibitors of tumor necrosis factor-a and mechanisms of their action. Arhiv za farmaciju 70:3, pages 109-129.
Crossref
Crossref
NAGACHIKA SUGISAKI, KURISU TADA, YOSHIYUKI ABE, MICHIHIRO OGASAWARA, RAN MATSUDAIRA, KEN YAMAJI, YOSHINARI TAKASAKI & NAOTO TAMURA. (2020) Clinical Efficacy and Factors Predictive of the Therapeutic Effect of the TNF Inhibitor Golimumab in Patients with Rheumatoid Arthritis. Juntendo Medical Journal 66:1, pages 38-45.
Crossref
Crossref
Doreen E. Szollosi & Clinton B. Mathias. 2020. Pharmacology of Immunotherapeutic Drugs. Pharmacology of Immunotherapeutic Drugs
43
66
.
Simon Krah, Ralf Günther, Stefan Becker, Stefan Zielonka & Laura Rhiel. 2020. Genotype Phenotype Coupling. Genotype Phenotype Coupling
335
349
.
Niels Graudal, Benjamin Skov Kaas-Hansen, Louise Guski, Thorbjørn Hubeck-Graudal, Nicky J. Welton & Gesche Jürgens. (2019) Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis—A Network Meta-Analysis of 36 Randomized Controlled Trials. International Journal of Molecular Sciences 20:18, pages 4350.
Crossref
Crossref
Erwin Dreesen, Wannee Kantasiripitak, Iris Detrez, Sebastian Stefanović, Séverine Vermeire, Marc Ferrante, Thomas Bouillon, David Drobne & Ann Gils. (2019) A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases.
Crossref
Crossref
Anne-Emmanuelle BergerGerard DuruAnnick de VriesJoseph C. MariniDjamila AouchetaFreddy CornillieStephane NanceyIris Detrez, Ann Gils, Xavier RoblinStephane Paul. (2019) Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study. Therapeutic Drug Monitoring 41:4, pages 459-466.
Crossref
Crossref
Nazlı Eda Kaleli, Murat Karadag & Sibel Kalyoncu. (2019) Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues. Proteins: Structure, Function, and Bioinformatics 87:7, pages 607-618.
Crossref
Crossref
Ashvini Reddy, Fauziyya Muhammad & Darren J. Lee. 2019. Advances in the Diagnosis and Management of Uveitis. Advances in the Diagnosis and Management of Uveitis.
Asma Khanniche, Ling Zhou, Bin Jiang, Jing Song, Yanhua Jin, Jian Yin, Shujun Wang, Ping Ji, Hao Shen, Ying Wang & Huji Xu. (2019) Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment. Frontiers in Immunology 10.
Crossref
Crossref
Honghui Zhou & Diane R. MouldSihem Ait-Oudhia, Yi Ting Kayla Lien, Sumit Basu, Lawrence Lesko & Stephan Schmidt. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
209
242
.
Muhammad Hassan, Samendra Karkhur, Jeong H. Bae, Muhammad S. Halim, Maria S. Ormaechea, Neil Onghanseng, Nam V. Nguyen, Rubbia Afridi, Yasir J. Sepah, Diana V. Do & Quan D. Nguyen. (2019) New therapies in development for the management of non‐infectious uveitis: A review. Clinical & Experimental Ophthalmology 47:3, pages 396-417.
Crossref
Crossref
Obinna C. Ubah, John Steven, Andrew J. Porter & Caroline J. Barelle. (2019) An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model. Frontiers in Immunology 10.
Crossref
Crossref
Silvia Menegatti, Elisabetta Bianchi & Lars Rogge. (2019) Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Frontiers in Immunology 10.
Crossref
Crossref
Rashmi Saxena Pal, Yogendra Pal, Ankita Wal & Pranay Wal. (2019) Current Review on Plant based Pharmaceutical Excipients. Open Medicine Journal 6:1, pages 1-5.
Crossref
Crossref
Gabriele Dragoni, Marco Le Grazie, Beatrice Orlandini & Francesca Rogai. (2018) Golimumab in inflammatory bowel diseases: present and future scenarios. Clinical Journal of Gastroenterology 12:1, pages 1-9.
Crossref
Crossref
Iris Detrez, Ganel Schops, Jolien Lefrère, Sophie Tops, Gert Van Assche, Séverine Vermeire, Wouter Van Moerkercke, Marc Ferrante & Ann Gils. (2018) Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. The AAPS Journal 21:1.
Crossref
Crossref
Georgina Cunningham, Mark A. Samaan & Peter M. Irving. (2019) Golimumab in the treatment of ulcerative colitis. Therapeutic Advances in Gastroenterology 12, pages 175628481882126.
Crossref
Crossref
Thomas Bourquard, Astrid Musnier, Vincent Puard, Shifa Tahir, Mohammed Akli Ayoub, Yann Jullian, Thomas Boulo, Nathalie Gallay, Hervé Watier, Gilles Bruneau, Eric Reiter, Pascale Crépieux & Anne Poupon. (2018) MAbTope: A Method for Improved Epitope Mapping. The Journal of Immunology 201:10, pages 3096-3105.
Crossref
Crossref
Ronan O’Dwyer, Marina Kovaleva, Jiquan Zhang, John Steven, Emma Cummins, Deborah Luxenberg, Alfredo Darmanin-Sheehan, Miguel F. Carvalho, Matthew Whitters, Kenneth Saunders & Caroline J. Barelle. (2018) Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis. Journal of Immunology Research 2018, pages 1-13.
Crossref
Crossref
Xiaobing Li, William J. Jusko & Yanguang Cao. (2018) Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. Journal of Pharmacology and Experimental Therapeutics 367:1, pages 1-8.
Crossref
Crossref
Kassem Sharif, Omer Gendelman, Pnina Langevitz, Tatiana Reitblat, Abdulla Watad, Yehuda Shoenfeld, Josef Azuri, Howard Amital, Nicola Luigi Bragazzi & Ora Shovman. (2018) Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice. Best Practice & Research Clinical Rheumatology 32:5, pages 692-700.
Crossref
Crossref
Brian Bressler, Martin Williamson, Bernie Sattin, Fernando Camacho & A Hillary Steinhart. (2018) Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. Journal of the Canadian Association of Gastroenterology 1:3, pages 129-134.
Crossref
Crossref
Sara Žigon-Branc, Ariana Barlič, Miomir Knežević, Matjaž Jeras & Gordana Vunjak-Novakovic. (2018) Testing the potency of anti-TNF-α and anti-IL-1β drugs using spheroid cultures of human osteoarthritic chondrocytes and donor-matched chondrogenically differentiated mesenchymal stem cells. Biotechnology Progress 34:4, pages 1045-1058.
Crossref
Crossref
Martin Bortlík. (2018) Conventional and biological therapy for inflammatory bowel disease. Vnitřní lékařství 64:6, pages 642-653.
Crossref
Crossref
Masatsugu Ono, Shoichiro Horita, Yumi Sato, Yayoi Nomura, So Iwata & Norimichi Nomura. (2018) Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab. Protein Science 27:6, pages 1038-1046.
Crossref
Crossref
Weirong Wang, Jocelyn Leu, Rebecca Watson, Zhenhua Xu & Honghui Zhou. (2018) Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody. The AAPS Journal 20:3.
Crossref
Crossref
Tomer Greener, Karen Boland, A Hillary Steinhart & Mark S Silverberg. (2018) The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease. Journal of Crohn's and Colitis 12:4, pages 458-464.
Crossref
Crossref
J. Scott Crowe, Kevin J. Roberts, Timothy M. Carlton, Luana Maggiore, Marion F. Cubitt, Simon Clare, Katherine Harcourt, Jill Reckless, Thomas T. MacDonald, Keith P. Ray, Anna Vossenkämper & Michael R. West. (2018) Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease. Scientific Reports 8:1.
Crossref
Crossref
Heejin Lim, Sang Lee, Hyun Lee, Jee Lee, Ji Son, Woori Shin & Yong-Seok Heo. (2018) Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. International Journal of Molecular Sciences 19:3, pages 768.
Crossref
Crossref
Victoria Hall, Douglas Johnson & Joseph Torresi. (2018) Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. Journal of Travel Medicine 25:1.
Crossref
Crossref
Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto & Naoyasu Ueda. (2018) Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists. Cytokine 101, pages 56-63.
Crossref
Crossref
C. Martineau, B. Flourié, P. Wils, T. Vaysse, R. Altwegg, A. Buisson, A. Amiot, G. Pineton de Chambrun, V. Abitbol, M. Fumery, X. Hébuterne, S. Viennot, D. Laharie, L. Beaugerie, S. Nancey & H. Sokol. (2017) Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Alimentary Pharmacology & Therapeutics 46:11-12, pages 1077-1084.
Crossref
Crossref
Maria Urdaneta, Hannah Jethwa, Reshma Sultan & Sonya Abraham. (2017) A review on golimumab in the treatment of psoriatic arthritis. Immunotherapy 9:11, pages 871-889.
Crossref
Crossref
Paul Declerck & Mourad Farouk Rezk. (2017) The road from development to approval: evaluating the body of evidence to confirm biosimilarity. Rheumatology 56:suppl_4, pages iv4-iv13.
Crossref
Crossref
Niels Vande Casteele & Reena Khanna. (2017) Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharmaceutical Research 34:8, pages 1556-1563.
Crossref
Crossref
Ping Li, Ying Zheng & Xin Chen. (2017) Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Frontiers in Pharmacology 8.
Crossref
Crossref
MA. Velasco-Velázquez, N. Salinas-Jazmín, E. Hisaki-Itaya, L. Cobos-Puc, W. Xolalpa, G. González, A. Tenorio-Calvo, N. Piña-Lara, LC. Juárez-Bayardo, LF. Flores-Ortiz, E. Medina-Rivero, NO. Pérez & SM. Pérez-Tapia. (2017) Extensive preclinical evaluation of an infliximab biosimilar candidate. European Journal of Pharmaceutical Sciences 102, pages 35-45.
Crossref
Crossref
Jonathan M. Blevitt, Michael D. Hack, Krystal L. Herman, Paul F. Jackson, Paul J. Krawczuk, Alec D. Lebsack, Annie X. Liu, Taraneh Mirzadegan, Marina I. Nelen, Aaron N. Patrick, Stefan Steinbacher, Marcos E. Milla & Kevin J. Lumb. (2017) Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein–Protein Interaction. Journal of Medicinal Chemistry 60:8, pages 3511-3517.
Crossref
Crossref
Abhinav Tiwari, Anson K. Abraham, John M. Harrold, Anup Zutshi & Pratap Singh. (2016) Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. The AAPS Journal 19:2, pages 510-519.
Crossref
Crossref
Aakash Aggarwal, Timothy Sabol & Haleh Vaziri. (2017) Update on the Use of Biologic Therapy in Ulcerative Colitis. Current Treatment Options in Gastroenterology 15:1, pages 155-167.
Crossref
Crossref
Shih-Chou Chen & Shwu-Jiuan Sheu. (2017) Recent advances in managing and understanding uveitis. F1000Research 6, pages 280.
Crossref
Crossref
Ines Harzallah, Josselin Rigaill, Nicolas Williet, Stephane Paul & Xavier Roblin. (2016) Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therapeutic Advances in Gastroenterology 10:1, pages 89-100.
Crossref
Crossref
Hyo-Deok Seo, Joong-jae Lee, Yu Jung Kim, Oliver Hantschel, Seung-Goo Lee & Hak-Sung Kim. (2017) Alkaline phosphatase-fused repebody as a new format of immuno-reagent for an immunoassay. Analytica Chimica Acta 950, pages 184-191.
Crossref
Crossref
S. Ndoja & H. Lima. 2017. Current Developments in Biotechnology and Bioengineering. Current Developments in Biotechnology and Bioengineering
71
95
.
S. Könemann, M. Dörr & S.B. Felix. 2017. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases
681
714
.
Calen A. Steiner, Emily P. Whitfield, Jeremy Adler & Peter D. R. Higgins. 2017. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
401
416
.
Mark A. Samaan & Peter M. Irving. 2017. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
441
448
.
Lene S. Høydahl, Nicolay R. Nilssen, Kristin S. Gunnarsen, M. Fleur du Pré, Rasmus Iversen, Norbert Roos, Xi Chen, Terje E. Michaelsen, Ludvig M. Sollid, Inger Sandlie & Geir Å. Løset. (2016) Multivalent pIX phage display selects for distinct and improved antibody properties. Scientific Reports 6:1.
Crossref
Crossref
Yu Zhou & James D. Marks. 2016. Biosimilars of Monoclonal Antibodies. Biosimilars of Monoclonal Antibodies
85
111
.
Maria Dolores Martin-Arranz. (2016) Monitoring Anti-Tnf Drug Treatment in Inflammatory Bowel Disease. Is it Useful in Clinical Practice?. Gastroenterology & Hepatology: Open Access 5:6.
Crossref
Crossref
Karin A. van Schie, Pleuni Ooijevaar-de Heer, Lisanne Dijk, Simone Kruithof, Gertjan Wolbink & Theo Rispens. (2016) Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. Scientific Reports 6:1.
Crossref
Crossref
Sarvajeet Pal, Sarath Chandra Mouli Veeravalli, Siddharth Kumar Das, Vineeta Shobha, Ramakrishna Rao Uppuluri, B G Dharmanand, Milind Nadkar, Elizabeth Hsia, Kaiyin Fei, Ruji Yao & Ahmed Khalifa. (2016) Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study. International Journal of Rheumatic Diseases 19:11, pages 1083-1092.
Crossref
Crossref
Zhanguo Li, Fengchun Zhang, Jonathan Kay, Kaiyin Fei, Chenglong Han, Yanli Zhuang, Zhong Wu & Elizabeth C. Hsia. (2016) Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. International Journal of Rheumatic Diseases 19:11, pages 1143-1156.
Crossref
Crossref
Antonio Tursi, Leonardo Allegretta, Nicola Della Valle, Yusef Hadad, Antonio Penna, Giuseppe Pranzo, Cristina Ricciardelli, Primaldo Paiano & Marcello Picchio. (2016) Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. Clinics and Research in Hepatology and Gastroenterology 40:5, pages e61-e63.
Crossref
Crossref
Takeharu Ogura, Yoshiyuki Tanaka & Hiromu Toyoda. (2016) Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. Analytical Biochemistry 508, pages 73-77.
Crossref
Crossref
María Chaparro & Javier P. Gisbert. (2016) Nuevas moléculas en el tratamiento de la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 39:6, pages 411-423.
Crossref
Crossref
María Chaparro & Javier P. Gisbert. (2016) New molecules in the treatment of inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 39:6, pages 411-423.
Crossref
Crossref
Iris Detrez, Erwin Dreesen, Thomas Van Stappen, Annick de Vries, Els Brouwers, Gert Van Assche, Séverine Vermeire, Marc Ferrante & Ann Gils. (2016) Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis. Journal of Crohn's and Colitis 10:5, pages 575-581.
Crossref
Crossref
Caroline Meyer Olesen, Mehmet Coskun, Laurent Peyrin-Biroulet & Ole Haagen Nielsen. (2016) Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology & Therapeutics 159, pages 110-119.
Crossref
Crossref
Valeria Rios Rodriguez & Denis Poddubnyy. (2016) Golimumab for treatment of axial spondyloarthritis. Immunotherapy 8:2, pages 107-115.
Crossref
Crossref
Won Moon. (2016) Golimumab Therapy in Ulcerative Colitis. The Korean Journal of Gastroenterology 67:2, pages 64.
Crossref
Crossref
Ulrike Billmeier, Walburga Dieterich, Markus F Neurath & Raja Atreya. (2016) Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World Journal of Gastroenterology 22:42, pages 9300.
Crossref
Crossref
Shrikant R. Mulay, Andreas Linkermann & Hans-Joachim Anders. (2016) Necroinflammation in Kidney Disease. Journal of the American Society of Nephrology 27:1, pages 27-39.
Crossref
Crossref
J. D. Isaacs, M. Cutolo, E. C. Keystone, W. Park & J. Braun. (2015) Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody. Journal of Internal Medicine 279:1, pages 41-59.
Crossref
Crossref
Preetika Sinh, Claudio Fiocchi & Jean-Paul Achkar. 2016. Immune Rebalancing. Immune Rebalancing
37
61
.
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy
141
215
.
Ariana Montes, Eva Perez-Pampin, Federico Navarro-Sarabia, Virginia Moreira, Arturo Rodríguez de la Serna, Berta Magallares, Yiannis Vasilopoulos, Theologia Sarafidou, Antonio Fernández-Nebro, María del Carmen Ordóñez, Javier Narváez, Juan D Cañete, Ana Marquez, Dora Pascual-Salcedo, Beatriz Joven, Patricia Carreira, Manuel J Moreno-Ramos, Rafael Caliz, Miguel Angel Ferrer, Rosa Garcia-Portales, Francisco J Blanco, Cesar Magro, Enrique Raya, Lara Valor, Juan J Alegre-Sancho, Alejandro Balsa, Javier Martin, Darren Plant, John Isaacs, Ann W Morgan, Anne Barton, Anthony G Wilson, Juan J Gómez-Reino & Antonio Gonzalez. (2015) Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study. Arthritis Research & Therapy 17:1.
Crossref
Crossref
Stephanie M. Slevin & Laurence J. Egan. (2015) New Insights into the Mechanisms of Action of Anti–Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 21:12, pages 2909-2920.
Crossref
Crossref
Salvador Mérida, Elena Palacios, Amparo Navea & Francisco Bosch-Morell. (2015) New Immunosuppressive Therapies in Uveitis Treatment. International Journal of Molecular Sciences 16:8, pages 18778-18795.
Crossref
Crossref
Ariana Barlič, Sara Žigon, Andrej Blejec & Nevenka Kregar Velikonja. (2015) Gene expression of cultured human chondrocytes as a model for assessing neutralization efficacy of soluble TNFα by TNFα antagonists. Biologicals 43:3, pages 171-180.
Crossref
Crossref
Yun-Na Song & Ping Zheng. (2015) Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 23:1, pages 1-10.
Crossref
Crossref
Khadija H. Chaudrey & Sunanda V. Kane. (2015) Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Current Treatment Options in Gastroenterology 13:1, pages 77-89.
Crossref
Crossref
Zhenhua Xu, Hugh M. Davis & Honghui Zhou. (2015) Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. The Journal of Clinical Pharmacology 55:S3, pages S60-S74.
Crossref
Crossref
Carlos Fernandes, Mariangela Allocca, Silvio Danese & Gionata Fiorino. (2015) Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 7:2, pages 175-190.
Crossref
Crossref
David B. Volkin, Susan Hershenson, Rodney J.Y. Ho, Susumu Uchiyama, Gerhard Winter & John F. Carpenter. (2015) Two Decades of Publishing Excellence in Pharmaceutical Biotechnology. Journal of Pharmaceutical Sciences 104:2, pages 290-300.
Crossref
Crossref
Peter C. Taylor. 2015. Rheumatology. Rheumatology
492
510
.
I. V. Astrakhantseva, G. A. Efimov, M. S. Drutskaya, A. A. Kruglov & S. A. Nedospasov. (2014) Modern anti-cytokine therapy of autoimmune diseases. Biochemistry (Moscow) 79:12, pages 1308-1321.
Crossref
Crossref
C. Bao, F. Huang, M. A. Khan, K. Fei, Z. Wu, C. Han & E. C. Hsia. (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology 53:9, pages 1654-1663.
Crossref
Crossref
Kirk Lin & Uma Mahadevan. (2014) Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring. Gastroenterology Clinics of North America 43:3, pages 565-579.
Crossref
Crossref
Gui Tran & Paul Emery. (2014) Role of golimumab for the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology 9:3, pages 245-258.
Crossref
Crossref
Arthur Kaser. (2014) Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease. Best Practice & Research Clinical Gastroenterology 28:3, pages 437-449.
Crossref
Crossref
Hans C. Ebbers. (2014) Biosimilars: In support of extrapolation of indications. Journal of Crohn's and Colitis 8:5, pages 431-435.
Crossref
Crossref
William J. Sandborn, Brian G. Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J. Adedokun, Cynthia Guzzo, Jean–Frederic Colombel, Walter Reinisch, Peter R. Gibson, Judith Collins, Gunnar Järnerot & Paul Rutgeerts. (2014) Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 146:1, pages 96-109.e1.
Crossref
Crossref
William J. Sandborn, Brian G. Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J. Adedokun, Cynthia Guzzo, Jean-Frederic Colombel, Walter Reinisch, Peter R. Gibson, Judith Collins, Gunnar Järnerot, Toshifumi Hibi & Paul Rutgeerts. (2014) Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 146:1, pages 85-95.
Crossref
Crossref
Maurizio Rossini, Salvatore De Vita, Clodoveo Ferri, Marcello Govoni, Giuseppe Paolazzi, Carlo Salvarani & Silvano Adami. (2013) Golimumab: A Novel Anti-Tumor Necrosis Factor. Biologics in Therapy 3:2, pages 83-107.
Crossref
Crossref
Arthur Kavanaugh, Iain B McInnes, Philip J Mease, Gerald G Krueger, Dafna D Gladman, Désirée van der Heijde, Surekha Mudivarthy, Weichun Xu, Michael Mack, Zhenhua Xu & Anna Beutler. (2013) Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Annals of the Rheumatic Diseases 72:11, pages 1777-1785.
Crossref
Crossref
Soha N. GhossainiJenny P. LiuBrett Phillips. (2013) Round window membrane permeability to golimumab in guinea pigs: A pilot study. The Laryngoscope 123:11, pages 2840-2844.
Crossref
Crossref
Tsutomu Takeuchi, Masayoshi Harigai, Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Nobuyuki Miyasaka, Takao Koike, Minoru Kanazawa, Takuya Oba, Toru Yoshinari & Daniel Baker. (2013) Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Annals of the Rheumatic Diseases 72:9, pages 1488-1495.
Crossref
Crossref
Seiji Minota. (2012) Physico-chemical characteristics of TNFα blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds. Modern Rheumatology 23:5, pages 1034-1036.
Crossref
Crossref
Lana M. Rifkin, Andrea D. Birnbaum & Debra A. Goldstein. (2013) TNF Inhibition for Ophthalmic Indications: Current Status and Outlook. BioDrugs 27:4, pages 347-357.
Crossref
Crossref
Masatoshi Hayashi, Tomonori Kobayakawa, Tetsuo Takanashi, Hideshi Yamazaki, Hisato Ishikawa & Toshihisa Kanamono. (2013) Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies. Clinical Rheumatology 32:7, pages 961-967.
Crossref
Crossref
Lauren M. Madigan, Benjamin H. Kaffenberger & Henry K. Wong. (2013) Bullae and psoriasiform hyperkeratosis after treatment with golimumab. Journal of the American Academy of Dermatology 68:6, pages e195-e196.
Crossref
Crossref
Theo Rispens, Pleuni Ooijevaar-de Heer, Ninotska I.L. Derksen, Gertjan Wolbink, Pauline A. van Schouwenburg, Simone Kruithof & Rob C. Aalberse. (2013) Nanomolar to sub-picomolar affinity measurements of antibody–antigen interactions and protein multimerizations: Fluorescence-assisted high-performance liquid chromatography. Analytical Biochemistry 437:2, pages 118-122.
Crossref
Crossref
Naoyasu Ueda, Hiroshi Tsukamoto, Hiroki Mitoma, Masahiro Ayano, Atsushi Tanaka, Shun-ichiro Ohta, Yasushi Inoue, Yojiro Arinobu, Hiroaki Niiro, Koichi Akashi & Takahiko Horiuchi. (2013) The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α. Inflammatory Bowel Diseases 19:6, pages 1224-1231.
Crossref
Crossref
Eisuke Shono. (2013) Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis. Drugs in R&D 13:1, pages 95-100.
Crossref
Crossref
XIXI MA & SHENGQIAN XU. (2013) TNF inhibitor therapy for rheumatoid arthritis. Biomedical Reports 1:2, pages 177-184.
Crossref
Crossref
Hideji Fujii, Yoshinori Murakami & Yasushi Harada. (2013) Pharmacological and clinical profile of golimumab （Simponi^|^reg;）. Folia Pharmacologica Japonica 141:5, pages 275-285.
Crossref
Crossref
Carl F. Ware. 2013. Immunopharmacology. Immunopharmacology
51
80
.
Vasco Filipe, Robert Poole, Olubukayo Oladunjoye, Kevin Braeckmans & Wim Jiskoot. (2012) Detection and Characterization of Subvisible Aggregates of Monoclonal IgG in Serum. Pharmaceutical Research 29:8, pages 2202-2212.
Crossref
Crossref
DIMITRIOS MAKRYGIANNAKIS & ANCA IRINEL CATRINA. (2012) Apoptosis as a Mechanism of Action of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis: Figure 1.. The Journal of Rheumatology 39:4, pages 679-685.
Crossref
Crossref
Yanli Zhuang, Zhenhua Xu, Bart Frederick, Dick E. de Vries, Joyce A. Ford, Monica Keen, Mittie K. Doyle, Kevin J. Petty, Hugh M. Davis & Honghui Zhou. (2012) Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study. Clinical Therapeutics 34:1, pages 77-90.
Crossref
Crossref
E-Chiang Lee & Michael Owen. 2012. Antibody Methods and Protocols. Antibody Methods and Protocols
137
148
.
Andrea T. Borchers, Naama Leibushor, Gurtej S. Cheema, Stanley M. Naguwa & M. Eric Gershwin. (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. Journal of Autoimmunity 37:4, pages 273-288.
Crossref
Crossref
Hyunbo Shim. (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Experimental and Molecular Medicine 43:10, pages 539.
Crossref
Crossref